Seminars in Oncology
Volume 31, Issue 6 , Pages 809-815 , December 2004

Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck

  • Michael Fanucchi

      Affiliations

    • Emory University-Winship Cancer Institute, Atlanta, GA USA
    • Corresponding Author InformationAddress reprint requests to Michael Fanucchi, MD, Emory Winship Cancer Institute, 550 Peachtree St, Glenn Building, Atlanta, GA 30308.
    • ,
  • Fadlo R. Khuri

      Affiliations

    • Emory University-Winship Cancer Institute, Atlanta, GA USA

References 

  1. Jemal A , Tiwari RC , Murray T , et al.   Cancer statistics . CA Cancer J Clin . 2004;54:8–29
  2. Brockstein B , Haraf D , Kies M , et al.   Survival, patterns of failure, and risk factors for recurrence after intensive concomitant chemoradiation (CRT) for squamous cell head and neck cancer (SCHNC) . Proc Am Soc Clin Oncol . 2002;21:918A; (abstr)
  3. Leon X , Hitt R , Constenia M , et al.   A retrospective analysis of the outcome of patients with recurrent or metastatic squamous cell carcinoma of the head and neck who are progressing on platinum-based palliative chemotherapy . Proc Am Soc Clin Oncol . 2003;22:502; (abstr 2022)
  4. Planting AS , Catimel G , de Mulder PH , et al.  EORTC Head and Neck Cooperative Group   Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer . Ann Oncol . 1999;10:693–700
  5. Jacobs C , Lyman G , Velez-Garcia E , et al.   A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck . J Clin Oncol . 1992;10:257–263
  6. Forastiere AA , Metch B , Schuller DE , et al.   Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck (A Southwest Oncology Group study) . J Clin Oncol . 1992;10:1245–1251
  7. Khuri FR , Shin DM , Glisson BS , et al.   Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (Current status and future directions) . Semin Oncol . 2000;27:25–33
  8. Forastiere A , Koch W , Trotti A , et al.   Head and neck cancer . N Engl J Med . 2001;345:1890–1900
  9. Kim ES , Glisson BS . Treatment of metastatic head and neck cancer (Chemotherapy and novel agents) . Cancer Treat Res . 2003;114:295–314
  10. Pivot X , Chamorey E , Guardiola E , Magne N , et al.   Phase I and pharmacokinetic study of the association of capecitabine-cisplatin ih head and neck cancer patients . Ann Oncol . 2003;14:1578–1586
  11. Forastiere AA . Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck . Semin Oncol . 1993;20:56–60
  12. Catimel G , Verweij J , Mattijssen V , et al.  EORTC Early Clinical Trials Group   Docetaxel (Taxotere) (An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck) . Ann Oncol . 1994;5:533–537
  13. Forastiere A , Leong T , Rowinsky E , et al.   Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer (Eastern Co-operative Oncology Group Study E1393) . J Clin Oncol . 2001;19:1088–1095
  14. (abstr) Murphy B , Li Y , Cella D , et al.   Phase III study comparing cisplatin and 5-flurouracil versus cisplatin and paclitaxel in metastatic/recurrent head and neck cancer . Proc Am Soc Clin Oncol . 2001;20:224a
  15. (abstr) Wells N , Murphy B , Dietrich M , et al.   Quality of life and pain assessment for head and neck cancer patients treated on E1395 (A comparison of two different cisplatin-based chemotherapy regimens) . Proc Am Soc Clin Oncol . 2002;21228A:
  16. Glisson B , Murphy B , Frenette G , et al.   Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck . J Clin Oncol . 2002;20:1593–1599
  17. Specht L , Larsen S , Hansen H . Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck . Ann Oncol . 2000;11:845–849
  18. Schoffski P , Catimel G , Planting AS , et al.   Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group . Ann Oncol . 1999;10:119–122
  19. Fountzilas G , Skarlos D , Athanassiades A , et al.   Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group . Ann Oncol . 1997;8:451–455
  20. Pivot X , Cals L , Cupissol D , et al.   Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neck . Oncology . 2001;60:66–71
  21. (abstr) Schroeder M , Holzgraefe M . Docetaxel-carboplatin for palliative chemotherapy in recurrent head and neck cancer . Proc Am Soc Clin Oncol . 2003;22508a:
  22. Degardin M , Cappelaere P , Krakowski I , et al.   Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck . Eur J Cancer B Oral Oncol . 1996;32B:278–279 (abstr)
  23. Debled M , Gervais R , Laguerre B , et al.   Phase II study of oxaliplatin in combination with 5-fluorouracil in first line treatment of locally advanced or metastatic squamous cell carcinoma of the head and neck . Proc Am Soc Clin Oncol . 2003;22:509a
  24. Shin DM , Glisson BS , Khuri FR , et al.   Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck . Semin Oncol . 1998;25:40–48
  25. Shin DM , Khuri FR , Glisson BS , et al.   Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma . Cancer . 2001;91:1316–1323
  26. Janinis J , Papadakou M , Xidakis E , et al.   Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer (A phase II feasibility study) . Am J Clin Oncol . 2000;23:128–131
  27. Catimel G , Vermorken JB , Clavel M , et al.  EORTC Early Clinical Trials Group   A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck . Ann Oncol . 1994;5:543–547
  28. Samlowski WE , Gundacker H , Kuebler JP , et al.   Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (A Southwest Oncology Group phase II study) . Invest New Drugs . 2001;19:311–315
  29. Hitt R , Castellano D , Hidalgo M , et al.   Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck . Ann Oncol . 1998;9:1347–1349
  30. Ma BB , Tannock IF , Pond GR , et al.   Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma . Cancer . 2002;95:2516–2523
  31. Ngan RK , Yiu HH , Lau WH , et al.   Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma (Report of a phase II study) . Ann Oncol . 2002;13:1252–1258
  32. Degardin M , Oliveira J , Geoffrois L , et al.   An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck . Ann Oncol . 1998;9:1103–1107
  33. Testolin A , Recher G , Cristoferi V , et al.   Vinorelbine in pre-treated advanced head & neck squamous cell carcinoma. A phase II study . Invest New Drugs . 1994;12:231–234
  34. Saxman S , Mann B , Canfield V , et al.   A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck . Am J Clin Oncol . 1998;21:398–400
  35. Espinosa E , Zamora P , Milla A , et al.   A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck . Head Neck . 2002;24:1054–1059
  36. Gebbia V , Testa A , Di Gregorio C , et al.   Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck . Am J Clin Oncol . 1995;18:293–296
  37. Gebbia V , Mantovani G , Agostara B , et al.   Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil (A multicenter phase II trial) . Ann Oncol . 1995;6:987–991
  38. Pivot X , Raymond E , Laguerre B , et al.   Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck . Br J Cancer . 2001;85:649–655
  39. Pivot X , Wadler S , Kelly C , et al.   Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer . Ann Oncol . 2001;12:1595–1599
  40. Samlowski WE , Lew D , Kuebler PJ , et al.   Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (A Southwest Oncology Group study) . Invest New Drugs . 1998;16:271–274
  41. Moroni M , Giannetta L , Gelosa G , et al.   Second-line chemotherapy with bleomycin, methotrexate, and vinorelbine (BMV) for patients with squamous cell carcinoma of the head, neck and esophagus (SCC-HN&E) pretreated with a cisplatin-containing regimen (A phase II study) . J Chemother . 2003;15:394–399
  42. (abstr) Cupissol D , Calais G , Tourani J , et al.   Phase II study of docetaxel plus gemcitabine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck . Proc Am Soc Clin Oncol . 2003;22:508a
  43. Airoldi M , Cattel L , Marchionatti S , et al.   Docetaxel and vinorelbine in recurrent head and neck cancer (Pharmacokinetic and clinical results) . Am J Clin Oncol . 2003;26:378–381
  44. Airoldi M , Cattel L , Cortesina G , et al.   Gemcitabine and vinorelbine in recurrent head and neck cancer (Pharmacokinetic and clinical results) . Anticancer Res . 2003;23:2845–2852
  45. Bischoff J , Kim D , Williams A , et al.   An adenovirus mutant that replicates selectively in p53-deficient tumor cells . Science . 1996;274:373–376
  46. Heise C , Sampson-Johannes A , Williams A , et al.   ONYX-015, an E1B gene- attenuated virus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents . Nat Med . 1997;3:639–645
  47. Nemunaitis J , Khuri FR , Ganly I , et al.   Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer . J Clin Oncol . 2001;19:289–298
  48. Ganly I , Eckhardt S , Rodriquez G , et al.   A phase I study of ONYX-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer . Clin Cancer Res . 2000;6:798–806
  49. Khuri FR , Nemunaitis J , Ganly I , et al.   A controlled trial of intratumoral ONYX- 015, a selectively-replicating adenovirus, in combination with cisplatin and 5- fluorouracil in patients with recurrent head and neck cancer . Nat Med . 2000;6:879–885
  50. Horio Y , Hasegawa Y , Sekido Y , et al.   Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells . Cancer Gene Ther . 2000;7:537–544
  51. Clayman G , El-Naggar A , Lippman SM , et al.   Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma . J Clin Oncol . 1998;16:2221–2232
  52. Nemunaitis J , Cunningham C , Buchanan A , et al.   Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients . Gene Ther . 2001;8:746–759
  53. Herbst R , Shin D . Monoclonal antibodies to target epidermal growth factor receptor-positive tumors . Cancer . 2002;94:1593–1611
  54. Cohen E , Rosen F , Dekker A , et al.   Phase II trial of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck . J Clin Oncol . 2003;21:1980–1987
  55. Cohen E , Stenson K , Gustin D , et al.   A phase II study of of 250 mg gefitinib (ZD1839) monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) . Proc Am Soc Clin Oncol . 2003;22:502; (abstr 2021)
  56. Shin DM , Donato N , Cooper M , et al.   Epidermal growth factor receptor targeted therapy with humanized chimeric monoclonal antibody, C225, in combination with cisplatin in patients with head and neck cancer . Clin Cancer Res . 2001;7:1204–1213
  57. Kies M , Arquette M , Nabell L , et al.   Final report of the efficacy and safety of the anti-epidermal growth factor antibody Eribitux (IMC-225) in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy . Proc Am Soc Clin Oncol . 2002;21:232A; (abstr)
  58. Baselga J , Trigo J , Bourhis J , et al.   Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen . Proc Am Soc Clin Oncol . 2002;21:226A; (abstr)
  59. Burtness B , Li Y , Flood W , et al.   Phase III study comparing cisplatin + placebo to cisplatin + anti-epidermal growth factor antibody C225 in patients with metastatic/recurrent head and neck cancer . Proc Am Soc Clin Oncol . 2002;21:226A; (abstr)
  60. Kies M , Clayman GL , El-Naggar AK , et al.   Induction therapy with SCH 6636, a farnesyl transferase inhibitor, in squamous cell carcinoma of the head and neck . Proc Am Soc Clin Oncol . 2001;20:896a; (abstr)
  61. Cohen EE , Rosen F , Stadler WM , et al.   Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck . J Clin Oncol . 2003;21:1980–1987

PII: S0093-7754(04)00411-7

doi: 10.1053/j.seminoncol.2004.09.014

Seminars in Oncology
Volume 31, Issue 6 , Pages 809-815 , December 2004

Article Tools

* Image Usage & Resolution